Adlai Nortye Ltd. (NASDAQ:ANL) Sees Large Decline in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 4,300 shares, a decline of 53.8% from the September 30th total of 9,300 shares. Based on an average daily trading volume, of 9,100 shares, the days-to-cover ratio is presently 0.5 days.

Adlai Nortye Stock Performance

Adlai Nortye stock traded down $0.01 during trading on Friday, reaching $2.08. 32,501 shares of the company were exchanged, compared to its average volume of 9,976. The stock's 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $5.40. Adlai Nortye has a 52-week low of $1.85 and a 52-week high of $17.48.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Adlai Nortye in a research report on Friday, October 18th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.